MEDIAN Technologies to Present Study Results at the 2013 European Cancer Congress (ECC) in Amsterdam

Regulatory News:

MEDIAN TECHNOLOGIES (Paris:ALMDT) (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced its participation in the European Cancer Congress (ECC), to be held next Sept. 27-Oct. 1, in Amsterdam, The Netherlands.

During the ECC — the premier European oncology conference, co-organized this year by the European Cancer Organization (ECCO), the European Society for Medical Oncology (ESMO) and the European Society for Radiotherapy and Oncology (ESTRO) — MEDIAN’s scientists will present the results of a study "Monitoring of Pulmonary Tumors in Computed Tomography: Thresholds for Volume-based Response Assessments and Target Lesions Selection” scheduled September 29 9:30 to 12:00 in Hall 4 - http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx (Abstract number 1150). Changes in lung tumor volume are emerging as a more sensitive imaging biomarker for disease evolution than uni-dimensional measurements of longest axial diameters. However, there are still missing scientific data to specify the magnitude of tumor volume changes that would allow classifying disease evolution and identifying if a patient responded to the therapy. This study proposes a solution for volume-based response assessments that provides thresholds for response, based on tumor volume, as well as a method for automatic identification of measurable lesions.

MEDIAN Technologies has also coauthored a poster publication presented by Saga University, Japan: "Evaluation of a Cloud-based Local Read Paradigm for Imaging Evaluations in Oncology Clinical Trials” scheduled September 29^th 9:30 to 12:00 in Hall 4 - http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx (Abstract number 1153). The goal of the study is to evaluate a cloud-based paradigm implementing software solutions and services that standardize imaging evaluations among international investigator sites. The study was performed using MEDIAN’s Lesion Management Solutions (LMS) and MEDIAN’s Clinical Trial Imaging Services (CTIS).

MEDIAN’s scientific and business development teams will be present at Booth 3567 to discuss study results and to give demonstrations of MEDIAN’s LMS solutions.

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the US. MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with Quintiles to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.

MEDIAN has received the label "Innovative company" by OSEO and is listed on NYSE Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).

For more information on MEDIAN, please visit: www.mediantechnologies.com